Nonetheless, the inhibitory effects on xenograft tumor growth were modest without tumor regression, suggesting that it may be inappropriate to use HO-1 inhibitors alone as a sole agent for the management of thyroid cancer in the clinical setting. The gene discussed is HMOX1; the disease is thyroid cancer.